Parathyroid carcinoma (PC) is remarkable for its rare occurrence and challenging diagnostics. PC accounts for 0.1–5 % cases of primary hyperparathyroidism (PHPT). The differentiation from benign tumours is difficult even by morphological criteria. To address these issues, we assessed the PC frequency in two separate European PHPT cohorts and evaluated the demographic, clinical, morphological and molecular background.
A retrospective study was carried out, using continuously maintained database (2005–2014) of PHPT patients from two tertiary referral university hospitals in Europe. The demographic, clinical data and frequency of PC among surgically treated PHPT was detected. Immunohistochemistry (IHC) was performed to detect parafibromin, representing protein product of HRPT2 gene and proliferation marker Ki-67.
Both PHPT cohorts were characterised by close mean age values (58.6 and 58.0 years) and female predominance. The frequency of PC differed significantly between the cohorts: 2.1 vs. 0.3 %; p = 0.004. PC was characterised by invariable complete loss of parafibromin contrasting with parathyroid adenomas. The proliferation fraction was similar in both PC cohorts (10.6 and 11.0 %). PC showed significantly higher proliferation fraction than typical parathyroid adenomas (1.6 %), atypical adenomas (1.6 %) or adenomas featuring focal loss of parafibromin (2.2 %).
PC frequency can range significantly between the two European cohorts. The differences can be attributable to selection bias of patients referred for surgery and are not caused by discordant definition of malignant parathyroid histology. Diffuse loss of parafibromin and increased proliferation fraction by Ki-67 are valuable adjuncts in PC diagnostics due to significant differences with various clinical and morphological subtypes of adenoma.
Cetani F, Banti C, Pardi E, Borsari S, Viacava P, Miccoli P, Torregrossa L, Basolo F, Pelizzo MR, Rugge M, Pennelli G, Gasparri G, Papotti M, Volante M, Vignali E, Saponaro F, Marcocci C (2013) CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer. Endocrine connections 2(4):186–195. doi: 10.1530/EC-13-0046 CrossRefPubMedPubMedCentral
Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1999) Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985–1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 86(3):538–544 CrossRefPubMed
Thompson L (2006) World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Ear Nose Throat J 85(2):74 PubMed
Witteveen JE, Hamdy NA, Dekkers OM, Kievit J, van Wezel T, Teh BT, Romijn JA, Morreau H (2011) Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma. Mod Pathol 24(5):688–697. doi: 10.1038/modpathol.2010.236 CrossRefPubMed
Wang O, Wang CY, Shi J, Nie M, Xia WB, Li M, Jiang Y, Guan H, Meng XW, Xing XP (2012) Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors. Chin Med J 125(16):2895–2901 PubMed
Guarnieri V, Battista C, Muscarella LA, Bisceglia M, de Martino D, Baorda F, Maiello E, D'Agruma L, Chiodini I, Clemente C, Minisola S, Romagnoli E, Corbetta S, Viti R, Eller-Vainicher C, Spada A, Iacobellis M, Malavolta N, Carella M, Canaff L, Hendy GN, Cole DE, Scillitani A (2012) CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort. Cell Oncol 35(6):411–422. doi: 10.1007/s13402-012-0100-x CrossRef
Lumachi F, Basso SM, Basso U (2006) Parathyroid cancer: etiology, clinical presentation and treatment. Anticancer Res 26(6C):4803–4807 PubMed
Zhao L, Liu JM, He XY, Zhao HY, Sun LH, Tao B, Zhang MJ, Chen X, Wang WQ, Ning G (2013) The changing clinical patterns of primary hyperparathyroidism in Chinese patients: data from 2000 to 2010 in a single clinical center. J Clin Endocrinol Metab 98(2):721–728. doi: 10.1210/jc.2012-2914 CrossRefPubMed
Murayama T, Kawabe K, Tagami M (1977) A case of parathyroid carcinoma concurred with hyperplasia: an electron microscopic study. J Urol 118(1 Pt 1):126–127 PubMed
Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3561–3569. doi: 10.1210/jc.2014-1413 CrossRefPubMed
Bilezikian JP, Silverberg SJ, Shane E, Parisien M, Dempster DW (1991) Characterization and evaluation of asymptomatic primary hyperparathyroidism. J Bone Miner Res Off J Am Soc Bone Miner Res 6(Suppl 2):S85–S89. doi: 10.1002/jbmr.5650061419, discussion S121-124
Levin KE, Galante M, Clark OH (1987) Parathyroid carcinoma versus parathyroid adenoma in patients with profound hypercalcemia. Surgery 101(6):649–660 PubMed
Gill AJ, Clarkson A, Gimm O, Keil J, Dralle H, Howell VM, Marsh DJ (2006) Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 30(9):1140–1149. doi: 10.1097/01.pas.0000209827.39477.4f CrossRefPubMed
Diaconescu MR, Glod M, Costea I, Grigorovici M, Diaconescu S (2015) Clinicopathological phenotype of parathyroid carcinoma: therapeutic and prognostic aftermaths. Chirurgia 110(1):66–71 PubMed
Kasaian K, Wiseman SM, Thiessen N, Mungall KL, Corbett RD, Qian JQ, Nip KM, He A, Tse K, Chuah E, Varhol RJ, Pandoh P, McDonald H, Zeng T, Tam A, Schein J, Birol I, Mungall AJ, Moore RA, Zhao Y, Hirst M, Marra MA, Walker BA, Jones SJ (2013) Complete genomic landscape of a recurring sporadic parathyroid carcinoma. J Pathol 230(3):249–260. doi: 10.1002/path.4203 CrossRefPubMed
- Evaluation of malignant parathyroid tumours in two European cohorts of patients with sporadic primary hyperparathyroidism
Peter E. Goretzki
- Springer Berlin Heidelberg
Neu im Fachgebiet Chirurgie
Mail Icon II